Effectiveness of Artificial Intelligence–Based Platform in Administering Therapies for Children With Autism Spectrum Disorder: 12-Month Observational Study
JMIR Neurotechnology · 2025-04-28 · 4 · e70589-e70589
DOI: 10.2196/70589 ↗Abstract
Abstract Background A 12-month longitudinal observational study was conducted on 43 children aged 2‐18 years to evaluate the effectiveness of the CognitiveBotics artificial intelligence (AI)–based platform in conjunction with continuous therapy in improving therapeutic outcomes for children with autism spectrum disorder (ASD). Objective This study evaluates the CognitiveBotics software’s effectiveness in supporting children with ASD through structured, technology-assisted learning. The primary objectives include assessing user engagement, tracking progress, and measuring efficacy using standardized clinical assessments. Methods A 12-month observational study was conducted on children diagnosed with ASD using the CognitiveBotics AI-based platform. Standardized assessments, include the Childhood Autism Rating Scale (CARS), Vineland Social Maturity Scale, Developmental Screening Test, and Receptive Expressive Emergent Language Test (REEL), were conducted at baseline (T1) and at the endpoint (T2). All participants meeting the inclusion criteria were provided access to the platform and received standard therapy. Participants who consistently adhered to platform use as per the study protocol were classified as the intervention group, while those who did not maintain continuous platform use were designated as the control group. Additionally, caregivers received structured training, including web-based parent teaching sessions, reinforcement strategy training, and home-based activity guidance. Results Participants in the intervention group demonstrated statistically significant improvements across multiple scales. CARS scores reduced from 33.41 (SD 1.89) at T1 to 28.34 (SD 3.80) at T2 ( P
EUVIMED